SCHEMBL2089124

SCHEMBL2089124

[O]COc1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
HPGD P15428 3/20 0.46
DAO P14920 1/20 0.46
KDM4E B2RXH2 3/20 0.45
MRGPRX4 Q96LA9 1/20 0.45
LMNA P02545 2/20 0.44
FKBP1A P62942 1/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
RECQL P46063 1/20 0.43
CYP3A4 P08684 1/20 0.43
CXCL8 P10145 1/20 0.43
ADRB2 P07550 1/20 0.42
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089979 0.82 L3MBTL1 (0.58) L3MBTL1TDP1HPGDKDM4EKMT2A
SCHEMBL575077 0.78 L3MBTL1 (0.59) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL1321165 0.76 L3MBTL1 (0.52) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL255562 0.76 L3MBTL1 (0.81) L3MBTL1TDP1HPGDKDM4ELMNA
SCHEMBL7938278 0.76 L3MBTL1 (0.52) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL7101264 0.76 L3MBTL1 (0.52) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL2089128 0.76 L3MBTL1 (0.52) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL29635708 0.76 L3MBTL1 (0.81) L3MBTL1TDP1HPGDKDM4ELMNA
SCHEMBL514459 0.76 L3MBTL1 (0.47) L3MBTL1TDP1HPGDDAOKDM4E
SCHEMBL249457 0.76 CTSS (0.60) L3MBTL1TDP1HPGDDAOKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 L3MBTL1 2575/4885TDP1 4548/4885HPGD 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.